STERLING WILL CONSIDER NAD CONCERNS IN FUTURE EXTRA STRENGTH BAYER PLUS ADS
This article was originally published in The Tan Sheet
STERLING WILL CONSIDER NAD CONCERNS IN FUTURE EXTRA STRENGTH BAYER PLUS ADS comparing the product to McNeil's Extra Strength Tylenol, the company told the National Advertising Division of the Council of Better Business Bureaus. NAD expressed the concern that a print ad claiming clinical proof that "a two-tablet dose" of Extra Strength Bayer Plus caused as little stomach upset as two tablets of Extra Strength Tylenol may not state clearly enough that only single doses of the analgesics were tested, according to a March 8 NAD Case Report.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC